Xeris Pharmaceuticals (NSDQ:XERS) said today that the FDA accepted its new drug application for a ready-to-use liquid glucagon rescue pen device.
The company’s product is designed to treat severe hypoglycemia in people with diabetes. The FDA is slated to make a decision about Xeris’ pen by June 10, 2019.
“The FDA acceptance of our NDA for review is an important milestone for Xeris. If approved, the Xeris glucagon rescue pen would be the first ready-to-use, liquid-stable glucagon in an auto-injector to treat severe hypoglycemia.
